Phase III trial (EORTC 18071 / CA184-029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health Related Quality of Life (HRQoL) results

INTRODUCTION: HRQoL was a secondary endpoint in the EORTC 18071 phase 3 trial in stage III melanoma patients comparing adjuvant Ipilimumab at 10 mg/kg (Ipi, N=475) versus placebo (Pbo, N=476). The primary endpoint was recurrence-free survival [HR (95% CI) = 0.75 (0.64–0.90); P=0.0013]. Toxicity of I...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Lancet Oncol
मुख्य लेखकों: Coens, Corneel, Suciu, Stefan, Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D., Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A., Richards, Jon M., Lebbe, Celeste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S., Maio, Michele, Kotapati, Srividya, de Pril, Veerle, Testori, Alessandro, Eggermont, Alexander
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2017
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5636622/
https://ncbi.nlm.nih.gov/pubmed/28162999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30015-3
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन